EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort

Alexandru-Florinel Oancea iD, Paula Cristina Morariu iD, Maria Godun, Stefan Dorin Dobreanu, Alexandru Jigoranu iD, Miron Mihnea, Diana Iosep, Ana Maria Buburuz, Radu Stefan Miftode iD, Diana-Elena Floria, Raluca Mitea, Cristina Gena Dascalu iD und 3 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Alexandru-Florinel Oancea und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Atrial Fibrillation, C-Reactive Protein, Serum Amyloid P-Component, Galectin 3. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy “Gr. T. Popa”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic coronary syndrome (CCS) and atrial fibrillation (AF) are prevalent cardiovascular conditions between whom there is a dual relationship, with significant morbidity and mortality. Recent studies have highlighted the roles of galectin-3 and pentraxin-3 as potential biomarkers in coronary atherosclerosis, yet their specific interactions and implications in patients with CCS and AF remain underexplored. This proof-of-concept study aimed to evaluate the levels of galectin-3 and pentraxin-3 in a cohort of patients with CCS and AF. A total of 131 patients diagnosed with CCS or/and AF were stratified based on coronary stenosis severity (significant, S-CCS and nonsignificant, N-CCS coronary lesions) and arrhythmia burden. Blood samples were collected to measure serum levels of galectin-3 and pentraxin-3 using enzyme-linked immunosorbent assay (ELISA) techniques. Clinical data, including demographic information, comorbidities, medication use, and biological markers of systemic inflammation, were recorded. The galectin-3 value was more than double in patients with S-CCS compared with those with N-CCS (17.39 ± 4.459 ng/mL versus 7.49 ± 2.732 ng/mL, p < 0.001). Atrial fibrillation was not associated with statistically significant variations in galectin-3 values, neither overall nor separately in the group of S-CCS or N-CCS. However, pentraxin-3 values were similar in S-CCS compared with those with N-CCS (2839.18 ± 1521.639 pg/mL versus 2564.07 ± 1299.055 pg/mL, p = 0.417). These values were lower in patients with sinus rhythm, with a mean of 2469.91 ± 1253.782 pg/mL, and steadily increased in those with paroxysmal, persistent, and permanent AF, for whom they reached a mean of 3162.87 ± 1893.068 pg/mL. Elevated levels of galectin-3 appear to correlate with coronary stenosis severity and may inform future strategies for risk stratification, patients’ selection for invasive coronarography or therapeutic targeting in CCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationC-Reactive ProteinSerum Amyloid P-ComponentGalectin 3HumansMaleBiomarkersFemaleMiddle AgedAgedCohort StudiesGalectinsBlood ProteinsPentraxins

Stichwörter der Autor:innen

atrial fibrillationbiomarkerschronic coronary syndromecoronary ischemic diseasegalectin-3pentraxin-3

Substanzen

BiomarkersC-Reactive ProteinSerum Amyloid P-ComponentGalectin 3GalectinsBlood ProteinsPentraxinsLGALS3 protein, human

Autor:innen und Institutionen

  • Faculty of Medicine, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.
  • Saint Spiridon Emergency Hospital, 700115 Iasi, Romania.
  • Faculty of Medicine Victor Papilian, University of Lucian Blaga, 550169 Sibiu, Romania.

ORCID-Profile: Alexandru-Florinel Oancea, Paula Cristina Morariu, Alexandru Jigoranu, Radu Stefan Miftode, Cristina Gena Dascalu, Daniela Maria Tanase, Mariana Floria

Förderung

  • University of Medicine and Pharmacy “Gr. T. Popa”

Zitieren

APA

Oancea, A. F., Morariu, P. C., Godun, M., Dobreanu, S. D., Jigoranu, A., Mihnea, M., Iosep, D., Buburuz, A. M., Miftode, R. S., Floria, D. E., Mitea, R., Dascalu, C. G., Tanase, D. M., Costache-Enache, I. I., & Floria, M. (2025). Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104909

Vancouver

Oancea AF, Morariu PC, Godun M, Dobreanu SD, Jigoranu A, Mihnea M, et al. Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104909

BibTeX
@article{Oancea2025,
  author = {Oancea, Alexandru-Florinel and Morariu, Paula Cristina and Godun, Maria and Dobreanu, Stefan Dorin and Jigoranu, Alexandru and Mihnea, Miron and Iosep, Diana and Buburuz, Ana Maria and Miftode, Radu Stefan and Floria, Diana-Elena and Mitea, Raluca and Dascalu, Cristina Gena and Tanase, Daniela Maria and Costache-Enache, Irina-Iuliana and Floria, Mariana},
  title = {Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104909}
}
Kostenlos starten →